My Treatment Approach: Recent Advances in the Treatment of Multiple Myeloma in Early Relapse : Episode 4

Video

August 25, 2022

Clinical Implications of the IKEMA Trial in R/R MM

Author(s):

Brea Lipe, MD,Peter Forsberg, MD

Dr Forsberg details the safety data and toxicity management strategies of the IKEMA clinical trial.

EP: 1.Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma

EP: 2.Treatment Options for Patients with Multiple Myeloma in Early Relapse

EP: 3.IKEMA Trial of Isatuximab plus Carfilzomib and Dexamethasone in R/R MM

Now Viewing

EP: 4.Clinical Implications of the IKEMA Trial in R/R MM

EP: 5.Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

EP: 6.Treatment of Patients With MM and High-Risk Cytogenetics

EP: 7.Patient Profile 2: A 76-Year-Old Female with R/R MM

EP: 8.CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

EP: 9.Selecting Patients for Treatment With DARA-Kd

EP: 10.Sequencing Therapies in Patients With R/R MM

EP: 11.Advice for Community Oncologists Treating Patients With R/R MM

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Related Content

March 18th 2025

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple Myeloma | Image Credit: © Свет Лана – stock.adobe.com

March 12th 2025

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com

February 28th 2025

CHMP Recommends Conditional Approval of Linvoseltamab for R/R Multiple Myeloma

February 27th 2025

The Rapid Evolution of Multiple Myeloma Treatment in Recent Years